ArticleBMC cancer2018
Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.BMC surgery · 2025Review
- Mechanisms and therapeutic strategies to combat the recurrence and progression of hepatocellular carcinoma after thermal ablation.Journal of interventional medicine · 2023Article
- Comparison of clinical efficacy between LAPS and ALPPS in the treatment of hepatitis B virus-related hepatocellular carcinoma.Gastroenterology report · 2023Article
- Loss of ficolin-3 expression is associated with poor prognosis in patients with hepatocellular carcinoma.International journal of medical sciences · 2023Article
- FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway.International journal of biological sciences · 2023Article
- Integrin alpha 6 is upregulated and drives hepatocellular carcinoma progression through integrin α6β4 complex.International journal of cancer · 2022Article
- How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?Cancers · 2022Article
- Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma.World journal of clinical cases · 2022Review
- Review
- Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation.Journal of hepatocellular carcinoma · 2022Review
- Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis.Frontiers in oncology · 2022Review
- Comprehensive Analysis of Prognostic Value and Immune Infiltration of Ficolin Family Members in Hepatocellular Carcinoma.Frontiers in genetics · 2022Article
- Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review.The Journal of international medical research · 2021Review
- Article
- Identification and Validation of Hub Genes Associated With Hepatocellular CarcinomaFrontiers in oncology · 2021Article
- The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2020Review
- Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.European radiology · 2019Review
- Combined locoregional-immunotherapy for liver cancer.Journal of hepatology · 2019Review
- Scutellaria barbata polysaccharides inhibit tumor growth and affect the serum proteomic profiling of hepatoma H22‑bearing mice.Molecular medicine reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundRadiofrequency ablation (RFA) can not only effectively kill hepatocellular carcinoma (HCC) tumour cells but also release tumour antigens that can provoke an immune response. However, there is no consensus regarding which antigens could constitutively be generated after RFA and could potentiate the immune response. The aim of this study was to identify these immune-potentiating antigens.
methodsWe performed two-dimensional electrophoresis (2-DE) and MALDI-TOF-MS/MS analyses on serum obtained before and after RFA from 5 HCC patients. Further validation for selected proteins was performed utilizing ELISA analysis on another 52 HCC patients. Disease-free survival (DFS) analysis according to the differential expression of the interested protein before and after RFA was performed.
resultsTwelve decreased and 6 increased proteins after RFA were identified by MS. Three proteins, including clusterin, Ficolin-3, and serum retinol binding protein-4, were further verified by ELISA on the 52 HCC patients. Only Ficolin-3 proved to be significantly changed after RFA. The 52 patients were divided into two groups according to the expression of Ficolin-3 before and after RFA. The 1-, 2- and 3-year DFS rates were 59.1%, 31.8%, and 22.7%, respectively, for patients in the low Ficolin-3 group (22 patients) and 73.3%, 60.0%, and 50.0%, respectively, for patients in the high Ficolin-3 group (30 patients) (P = 0.038).
conclusionsIn conclusion, Ficolin-3 was overexpressed in the serum of most HCC patients after RFA. Ficolin-3 might be a biomarker for RFA treatment efficacy and a potential target for HCC immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.